Humanized antibodies with increased stability

Patent metadata

Field	Value
Publication number	US-11066470-B2
Application number	US-201916398472-A
Country	US
Kind code	B2
Filing date	Apr 30, 2019
Priority date	Mar 14, 2014
Publication date	Jul 20, 2021
Grant date	Jul 20, 2021

Abstract

The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

First claim

We claim:

1. Recombinant nucleic acids encoding an antibody or antibody fragment that binds to a KIR3DL2 polypeptide, selected from the group consisting of:
(a) an antibody or antibody fragment comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 31 and 25,
(b) an antibody or antibody fragment comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 31 and 26,
(c) an antibody or antibody fragment comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 14 and 9, and
(d) an antibody or antibody fragment comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 15 and 9.

2. The nucleic acids of claim 1 , wherein the antibody or antibody fragment comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 14; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9.

3. The nucleic acids of claim 1 , wherein the antibody or antibody fragment comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9.

4. The nucleic acids of claim 1 , wherein the antibody or antibody fragment comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 25.

5. The nucleic acids of claim 1 , wherein the antibody or antibody fragment comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26.

6. The nucleic acids of claim 1 , wherein said antibody comprises a human heavy chain constant region comprising amino acid substitution(s) that increase binding to a human FcγIIIA (CD16) receptor.

7. A host cell comprising the nucleic acids of claim 1 .

8. The host cell of claim 7 , wherein the host cell is co-transfected with a vector comprising a nucleic acid encoding a variable heavy (VH) region and with a vector comprising a nucleic acid encoding a variable light (VL) region, wherein:
a) the VH and VL region comprise the amino acid sequence of SEQ ID NOS: 31 and 25, respectively;
(b) the VH and VL region comprise the amino acid sequence of SEQ ID NOS: 31 and 26, respectively;
(c) the VH and VL region comprise the amino acid sequence of SEQ ID NOS: 14 and 9, respectively; or
(d) the VH and VL region comprise the amino acid sequence of SEQ ID NOS: 15 and 9, respectively.

9. The host cell of claim 8 , wherein the VH and VL regions comprise the amino acid sequence of SEQ ID NOS: 31 and 25, respectively.

10. The host cell of claim 8 , wherein the VH and VL regions comprise the amino acid sequence of SEQ ID NOS: 31 and 26, respectively.

11. The host cell of claim 8 , wherein the VH and VL regions comprise the amino acid sequence of SEQ ID NOS: 14 and 9, respectively.

12. The host cell of claim 8 , wherein the VH and VL regions comprise the amino acid sequence of SEQ ID NOS: 15 and 9, respectively.

13. A method of producing an antibody or antibody fragment that binds to a KIR3DL2 polypeptide, the method comprising culturing host cells of claim 7 and recovering the antibody or antibody fragment from the host cell culture.

Assignees

• Innate Pharma

Inventors

• Gauthier Laurent
• Schneider Nicolas

Classifications

• A61K39/39533

  against materials from animals · CPC title

• C07K16/2803 Primary

  against the immunoglobulin superfamily · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61K47/12

  Carboxylic acids; Salts or anhydrides thereof · CPC title